Eli Lilly's investigational amylin receptor agonist, eloralintide, demonstrated 'clinically meaningful' weight loss in a phase 2 trial. The highest dose achieved up to 20.1% weight reduction at 48 weeks. The drug showed an acceptable tolerability profile, particularly when using dose escalation to mitigate gastrointestinal side effects.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.